publication . Article . Other literature type . 2015

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome

Michael eRafii; Hannah eWishnek; James eBrewer; Michael eDonohue; Seth eNess; William eMobley; Paul eAisen; Robert eRissman;
Open Access
  • Published: 14 Sep 2015
  • Publisher: eScholarship, University of California
  • Country: Mexico
Abstract
To gain further knowledge on the preclinical phase of AD, we sought to characterize cognitive performance, volumetric MRI, amyloid PET, FDG PET, retinal amyloid, and plasma biomarkers in a cohort of non-demented adults with Down Syndrome (DS). The goal of the Down Syndrome Biomarker Initiative (DSBI) pilot is to test feasibility of this approach for future multicenter studies. We enrolled 12 non-demented participants with DS between the ages of 30-60 years old. Participants underwent extensive cognitive testing, volumetric MRI, amyloid PET 18F-florbetapir, 18F-fluorodeoxyglucose (18F-FDG) PET, and retinal amyloid imaging. In addition, plasma beta-amyloid species...
Subjects
Medical Subject Headings: mental disorders
free text keywords: Alzheimer’s disease, MRI, PET, amyloid, biomarkers, down syndrome, plasma, retinal, Neurosciences, Psychology, Cognitive Sciences, Neuroscience, Original Research, Retina, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Effects of sleep deprivation on cognitive performance, Alzheimer's disease biomarkers, Apolipoprotein E, Population, education.field_of_study, education, Pathology, medicine.medical_specialty, medicine, medicine.disease, Biomarker (medicine), Cohort, business.industry, business
Related Organizations
44 references, page 1 of 3

Beacher F.Daly E.Simmons A.Prasher V.Morris R.Robinson C.. (2010). Brain anatomy and ageing in non-demented adults with down’s syndrome: an in vivo MRI study. Psychol. Med.40, 611–619. 10.1017/s0033291709990985 19671216 [OpenAIRE] [PubMed] [DOI]

Benjamini Y.Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 57, 289–300.

Blessed G.Black S. E.Butler T.Kay D. W. (1991). The diagnosis of dementia in the elderly. A comparison of CAMCOG (th e cognitive section of CAMDEX), the AGECAT program, DSM-III, the Mini-Mental State Examination and some short rating scales. Br. J. Psychiatry 159, 193–198. 10.1192/bjp.159.2.193 1773235 [OpenAIRE] [PubMed] [DOI]

Brewer J. B.Magda S.Airriess C.Smith M. E. (2009). Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. AJNR Am. J. Neuroradiol. 30, 578–580. 10.3174/ajnr.a1402 19112065 [OpenAIRE] [PubMed] [DOI]

Coppus A. M.Evenhuis H. M.Verberne G. J.Visser F. E.Arias-Vasquez A.Sayed-Tabatabaei F. A.. (2008). The impact of apolipoprotein E on dementia in persons with down’s syndrome. Neurobiol. Aging 29, 828–835. 10.1016/j.neurobiolaging.2006.12.013 17250929 [OpenAIRE] [PubMed] [DOI]

Dalton A. J. (1992). Dementia in down syndrome: methods of evaluation. Prog. Clin. Biol. Res. 379, 51–76. 1409753 [PubMed]

Deb S.Braganza J.Norton N.Williams H.Kehoe P. G.Williams J.. (2000). APOE epsilon 4 influences the manifestation of Alzheimer’s disease in adults with down’s syndrome. Br. J. Psychiatry 176, 468–472. 10.1192/bjp.176.5.468 10912224 [OpenAIRE] [PubMed] [DOI]

Donohue M. C.Moghadam S. H.Roe A. D.Sun C. K.Edland S. D.Thomas R. G.. (2014). Longitudinal plasma amyloid beta in Alzheimer’s disease clinical trials. Alzheimers. Dement. [Epub ahead of print]. 10.1016/j.jalz.2014.07.156 25301682 [OpenAIRE] [PubMed] [DOI]

Esbensen A. J.Rojahn J.Aman M. G.Ruedrich S. (2003). Reliability and validity of an assessment instrument for anxiety, depression and mood among individuals with mental retardation. J. Autism Dev. Disord. 33, 617–629. 10.1023/b:jadd.0000005999.27178.55 14714931 [OpenAIRE] [PubMed] [DOI]

Fischl B.Salat D. H.Busa E.Albert M.Dieterich M.Haselgrove C.. (2002). Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341–355. 10.1016/S0896-6273(02)00569-X 11832223 [OpenAIRE] [PubMed] [DOI]

Gonzalez L. M.Anderson V. A.Wood S. J.Mitchell L. A.Heinrich L.Harvey A. S. (2008). The observer memory questionnaire-parent form: introducing a new measure of everyday memory for children. J. Int. Neuropsychol. Soc. 14, 337–342. 10.1017/s135561770808020x 18282331 [OpenAIRE] [PubMed] [DOI]

Goodenough F. L.Harris D. (1950). Studies in the psychology of children’s drawings. II. 1928–1949. Psychol. Bull. 47, 369–433. 10.1037/h0058368 14776171 [OpenAIRE] [PubMed] [DOI]

Handen B. L.Cohen A. D.Channamalappa U.Bulova P.Cannon S. A.Cohen W. I.. (2012). Imaging brain amyloid in nondemented young adults with down syndrome using pittsburgh compound B. Alzheimers. Dement.8, 496–501. 10.1016/j.jalz.2011.09.229 23102120 [OpenAIRE] [PubMed] [DOI]

Hartley S. L.Handen B. L.Devenny D. A.Hardison R.Mihaila I Price J. C.. (2014). Cognitive functioning in relation to brain amyloid-ß in healthy adults with Down syndrome. Brain 137(Pt. 9), 2556–2563. 10.1093/brain/awu173 24993958 [OpenAIRE] [PubMed] [DOI]

Heister D.Brewer J. B.Magda S.Blennow K.McEvoy L. K.Alzheimer’s Disease Neuroimaging I. (2011). Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619–1628. 10.1212/wnl.0b013e3182343314 21998317 [OpenAIRE] [PubMed] [DOI]

44 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2015

The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in down syndrome

Michael eRafii; Hannah eWishnek; James eBrewer; Michael eDonohue; Seth eNess; William eMobley; Paul eAisen; Robert eRissman;